Puma Biotechnology and Pierre Fabre enter into an exclusive license agreement for the development and marketing of NERLYNX® (neratinib)
Tuesday, April 02, 2019
Puma Biotechnology, Inc and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and market NERLYNX® (neratinib) in Europe and in some regions of Africa. In September 2018, the European Commission granted the marketing authorization for NERLYNX® (neratinib) for the extended adjuvant treatment of adult patients with early-stage breast cancer-positive HER2 receptor-positive breast cancer who completed less. a year's previous trastuzumab-based adjuvant therapy.
The original text of this announcement, written in the source language, is the official version that is authentic. The translations are offered solely for the reader's convenience and must refer to the text in the original language, which is the only legally valid one.
